Idiopathic Pulmonary Fibrosis
Progressive pulmonary fibrosis: an expert group consensus statement
Eur Respir J. 2022 Dec 14:2103187. doi: 10.1183/13993003.03187-2021. Online ahead of print.
NO ABSTRACT
PMID:36517177 | DOI:10.1183/13993003.03187-2021
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8.
NO ABSTRACT
PMID:36514019 | DOI:10.1186/s12890-022-02281-8
Dyspnea: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition
Eur J Phys Rehabil Med. 2022 Dec 13. doi: 10.23736/S1973-9087.22.07805-4. Online ahead of print.
NO ABSTRACT
PMID:36511169 | DOI:10.23736/S1973-9087.22.07805-4
Reactivation of tuberculosis in patient treated with the antifibrotic drug nintedanib
Int J Mycobacteriol. 2022 Oct-Dec;11(4):454-456. doi: 10.4103/ijmy.ijmy_194_22.
NO ABSTRACT
PMID:36510934 | DOI:10.4103/ijmy.ijmy_194_22
Prognosis of IPF patients with comorbid lung cancer: Preventing immortal time bias will make the analysis more valuable
Respirology. 2022 Dec 12. doi: 10.1111/resp.14436. Online ahead of print.
NO ABSTRACT
PMID:36509428 | DOI:10.1111/resp.14436
Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies
Front Med (Lausanne). 2022 Nov 24;9:959010. doi: 10.3389/fmed.2022.959010. eCollection 2022.
NO ABSTRACT
PMID:36507532 | PMC:PMC9729277 | DOI:10.3389/fmed.2022.959010
Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study
Int J Mol Sci. 2022 Dec 2;23(23):15205. doi: 10.3390/ijms232315205.
NO ABSTRACT
PMID:36499525 | PMC:PMC9738037 | DOI:10.3390/ijms232315205
B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis
Int J Mol Sci. 2022 Nov 30;23(23):15040. doi: 10.3390/ijms232315040.
NO ABSTRACT
PMID:36499368 | DOI:10.3390/ijms232315040
Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice
Int J Mol Sci. 2022 Nov 30;23(23):15027. doi: 10.3390/ijms232315027.
NO ABSTRACT
PMID:36499351 | DOI:10.3390/ijms232315027
Cell-Specific Response of NSIP- and IPF-Derived Fibroblasts to the Modification of the Elasticity, Biological Properties, and 3D Architecture of the Substrate
Int J Mol Sci. 2022 Nov 25;23(23):14714. doi: 10.3390/ijms232314714.
NO ABSTRACT
PMID:36499041 | DOI:10.3390/ijms232314714
A Proof-of-Concept Analysis of Plasma-Derived Exosomal microRNAs in Interstitial Pulmonary Fibrosis Secondary to Antisynthetase Syndrome
Int J Mol Sci. 2022 Nov 23;23(23):14579. doi: 10.3390/ijms232314579.
NO ABSTRACT
PMID:36498905 | DOI:10.3390/ijms232314579
Idiopathic Pulmonary Fibrosis and Telomeres
J Clin Med. 2022 Nov 22;11(23):6893. doi: 10.3390/jcm11236893.
NO ABSTRACT
PMID:36498467 | DOI:10.3390/jcm11236893
Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series
Chest. 2022 Dec;162(6):e311-e316. doi: 10.1016/j.chest.2022.08.2213.
NO ABSTRACT
PMID:36494131 | PMC:PMC9723271 | DOI:10.1016/j.chest.2022.08.2213
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Respir Res. 2022 Dec 9;23(1):334. doi: 10.1186/s12931-022-02273-6.
NO ABSTRACT
PMID:36494685 | DOI:10.1186/s12931-022-02273-6
CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis
Clin Imaging. 2022 Dec 5;94:42-49. doi: 10.1016/j.clinimag.2022.11.022. Online ahead of print.
NO ABSTRACT
PMID:36493681 | DOI:10.1016/j.clinimag.2022.11.022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis
EClinicalMedicine. 2022 Dec 1;55:101758. doi: 10.1016/j.eclinm.2022.101758. eCollection 2023 Jan.
NO ABSTRACT
PMID:36483266 | PMC:PMC9722446 | DOI:10.1016/j.eclinm.2022.101758
Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19
medRxiv. 2022 Nov 29:2022.11.28.22282811. doi: 10.1101/2022.11.28.22282811. Preprint.
NO ABSTRACT
PMID:36482970 | PMC:PMC9727772 | DOI:10.1101/2022.11.28.22282811
Role of the occupational disease consultant in the multidisciplinary discussion of interstitial lung diseases
Respir Res. 2022 Dec 8;23(1):332. doi: 10.1186/s12931-022-02257-6.
NO ABSTRACT
PMID:36482462 | DOI:10.1186/s12931-022-02257-6
Real-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis
Adv Ther. 2022 Dec 8. doi: 10.1007/s12325-022-02382-0. Online ahead of print.
NO ABSTRACT
PMID:36481866 | DOI:10.1007/s12325-022-02382-0
DACT2 protects against pulmonary fibrosis via suppressing glycolysis in lung myofibroblasts
Int J Biol Macromol. 2022 Dec 5:S0141-8130(22)02889-6. doi: 10.1016/j.ijbiomac.2022.11.324. Online ahead of print.
NO ABSTRACT
PMID:36481337 | DOI:10.1016/j.ijbiomac.2022.11.324